Tandem Diabetes Care, Inc. TNDM shares rallied 7.7% in the last trading session to close at $17.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 31.4% loss over the past four weeks.
Tandem Diabetes scored a strong price increase, driven by investor’s optimism surrounding strong progress across its strategic initiatives, operational momentum and improving financial performance. The company shipped nearly 33,000 pumps worldwide in the second quarter of 2026, driven by the continued demand for Control-IQ, product innovations, and enhanced channel access. Tandem Diabetes also launched t:slim X2 Insulin pump compatibility with Abbott FreeStyle Libre 3 Plus Sensor across five international markets.
This company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +16.1%. Revenues are expected to be $265.01 million, up 6.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Tandem Diabetes Care, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TNDM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Tandem Diabetes Care belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Treace Medical Concepts TMCI, closed the last trading session 0.4% lower at $4.56. Over the past month, TMCI has returned 2.9%.
For Treace Medical Concepts, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.26. This represents no change from what the company reported a year ago. Treace Medical Concepts currently has a Zacks Rank of #2 (Buy).
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report
Treace Medical Concepts, Inc. (TMCI): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).